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Abstract
Background: Fleas are a ubiquitous ectoparasite infesting dogs and cause direct discomfort, allergic reactions and
are responsible for the transmission of several pathogens. The rapid speed of kill of a parasiticide is important to
alleviate the direct deleterious effects of fleas, reduce the impact of allergic responses, and break the flea life cycle.
In this study, the speed of kill of a novel orally administered isoxazoline parasiticide, sarolaner (Simparica™) against
fleas on dogs was evaluated and compared with spinosad in combination with milbemycin oxime (Trifexis®) for
5 weeks after a single oral dose.
Methods: Twenty-four dogs were randomly allocated to treatment with a single oral dose per product label of
sarolaner (2 to 4 mg/kg), spinosad/milbemycin oxime (30 to 60 mg/kg / 0.2 to 0.4 mg/kg), or placebo based on
pretreatment flea counts. Dogs were combed and live fleas counted at 8, 12, and 24 h after treatment and
subsequent re-infestations on Days 7, 14, 21, 28, and 35. Efficacy (reduction in live flea counts) of each treatment
was determined at each time point relative to counts for placebo dogs.
Results: There were no adverse reactions to treatment. A single oral dose of sarolaner provided ≥94.0 % efficacy
(based on geometric means) within 8 h of treatment or subsequent weekly re-infestations of fleas to Day 35. By
12 h, fleas were eradicated from all dogs and they remained flea free at 24 h. Significantly greater numbers of live
fleas were recovered from spinosad/milbemycin oxime-treated dogs at 8 h from Day 21 to Day 35 (P≤ 0.0085), and
at 12 and 24 h on Day 35 (P ≤ 0.0002).
Conclusions: In this controlled laboratory evaluation, dogs treated with sarolaner had significantly fewer live fleas
than spinosad/milbemycin oxime- treated dogs at 8 h after re-infestation from Day 21 after a single oral dose. The
rapid and consistent kill of fleas after a single oral dose of sarolaner over 35 days indicates that this treatment
should provide highly effective control of flea infestations, relief for dogs afflicted with flea allergy dermatitis, and
also reduce the risk of transmission of flea-borne pathogens.
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Background
The cat flea, Ctenocephalides felis felis, is the most com-
mon ectoparasite of dogs and cats worldwide [1], flea in-
festation of pets and the home is common and control
can be expensive and time consuming [2]. Flea bites can
elicit an allergic response, flea allergic dermatitis (FAD),
causing intense pruritus and severe skin inflammation
[3]. Fleas can also transmit a number of bacterial patho-
gens and are the intermediate host for filarid and
cestode parasites [4–9]. Fleas feed almost immediately
on attaining a host [10], and direct irritation and allergic
reactions are dependent upon the frequency and dur-
ation of feeding [11]. Thus, the rapid kill of fleas is desir-
able to alleviate both the immediate irritation caused by
fleas as well as to reduce associated allergenic responses
and the risk of flea-borne pathogen transmission; this may
include on-host flea treatment as well as environmental
treatment to reduce the household infestation [2]. The
speed of kill of adult fleas on the host is also an important
factor in the control of infestations, as female fleas do not
begin producing eggs until 24 to 48 h after they start feed-
ing [12]. Killing fleas before they lay eggs will, over time,
effectively control the environmental infestation.
The use of highly effective parasiticides has allowed
the primary means of flea control to be via direct treat-
ment of the pet. Their use, as host-targeted therapies,
markedly reduces the severity and prevalence of FAD
and has reduced the need to treat indoor and outdoor
environments [1]. Orally administered compounds have
been introduced that provide rapid systemic control of
fleas for up to 24 to 48 h like nitenpyram [13] or for up
to a month, spinosad [14]. These products have been
widely accepted by veterinarians and dog owners for
their efficacy, ease of use and, since these agents are not
topically applied, the potential lower exposure of the
owner or children to residues. Newer isoxazoline com-
pounds (e.g. fluralaner and afoxolaner) have demon-
strated efficacy against fleas and also ticks for a month
or longer following a single orally administered dose
[15, 16]. Sarolaner (Simparica™, Zoetis) is a new isoxazo-
line effective against fleas and ticks for at least one
month following a single oral dose. A laboratory study
was conducted to compare the speed of kill of a single dose
of sarolaner (Simparica™, Zoetis) and spinosad/milbemycin
oxime (Trifexis®, Elanco) against an existing flea (C. felis)




This laboratory efficacy study was a masked, negative con-
trolled, randomized complete block design conducted in
Arkansas, USA. Procedures were in accordance with the
World Association for the Advancement of Veterinary
Parasitology (WAAVP) guidelines for evaluating the effi-
cacy of parasiticides for the treatment, prevention and
control of flea and tick infestation on dogs and cats [17]
and complied with the principles of Good Clinical Prac-
tices [18]. The protocol was reviewed and approved by the
local Institutional Animal Care and Use Committee.
Masking of the study was assured through the separation
of functions. All personnel conducting observations or
animal care or performing infestations and counts were
masked to treatment allocation.
Animals
Twenty-four, male and female, purpose-bred mongrel
dogs from 7 to 35 months of age and weighing from 5.4
to 14.6 kg were used in the study. All dogs had under-
gone an adequate wash-out period to ensure that no re-
sidual ectoparasiticide efficacy remained from any
previously administered compound. Each dog was indi-
vidually identified by electronic transponder or ear tat-
too. The dogs were acclimatized to study conditions for
a minimum of 14 days before treatment on Day 0. Dogs
were individually housed in indoor runs such that no
physical contact was possible between them. Dogs were
fed an appropriate maintenance ration of a commercial
dry canine feed, and water was available ad libitum. All
dogs were given a physical examination to evaluate gen-
eral health and suitability for inclusion into the study.
General health observations were performed at least
once daily from the start of the acclimation period to
the end of the study.
Design
The study followed a randomized complete block design.
Dogs were ranked according to decreasing flea counts into
blocks of three and within each block a dog was randomly
allocated to treatment with placebo, sarolaner, or spino-
sad/milbemycin oxime. There were eight dogs per treat-
ment group. Dogs were infested with fleas prior to
treatment and then weekly following treatment for 5
weeks. Flea counts were conducted at 8, 12, and 24 h after
treatment and after each subsequent weekly re-infestation.
Treatment
Day -2 bodyweights were used to determine the appro-
priate dose to be administered. On Day 0, dogs re-
ceived either a placebo tablet, a sarolaner chewable
tablet (Simparica™) to deliver sarolaner at the minimum
label dose of 2 mg/kg (range 2 to 4 mg/kg), or Trifexis®
per US label directions (spinosad at 30 to 60 mg/kg
plus milbemycin oxime at 0.2 to 0.4 mg/kg). All doses
were administered by hand pilling to ensure accurate
and complete dosing. Each dog was observed for sev-
eral minutes after dosing for evidence that the dose
was swallowed, and for general health at 1, 4, and 24 h
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after treatment administration. In order to comply
with Trifexis® label requirements, all dogs were offered
their regular ration within 30 min of treatment.
Flea infestation and assessment
The C. felis used in the study were from a locally main-
tained laboratory colony initiated in 2004 with fleas from
a laboratory colony in North Carolina, USA. Wild
caught fleas locally obtained in Arkansas were intro-
duced into the colony approximately six months prior to
study initiation. Flea infestations were performed on
Days -7 (host suitability and allocation), -2, 7, 14, 21, 28
and 35. At each infestation a pre-counted aliquot of 100
(±5) adult, unfed C. felis were directly applied to the ani-
mal which was gently restrained for a few minutes to
allow the fleas to penetrate and disperse into the hair
coat. Each dog was examined and combed to remove
and count fleas at 24 h after the initial host suitability in-
festation, and at 8, 12, and 24 (±1) hours after treatment
and each subsequent weekly re-infestation. Fleas were
replaced on the dogs immediately after each 8 and 12 h
evaluation, and discarded after the 24 h counts.
Flea counts were performed by personnel trained in the
standard procedures in use at the test facility. Commercial
fine-toothed flea combs were used. Dogs were combed
using repeated strokes initially while standing starting
from the head, then proceeding caudally along the dor-
sum. The dog was then placed on each side and then on
its back for combing of the sides and ventral surfaces.
After a few combing strokes were completed, the comb
was examined and hair and fleas were removed from the
comb and all live fleas were counted. Each animal was
combed for a minimum of 10 min; if any fleas were recov-
ered in the last minute, combing was continued in one-
minute increments until no fleas were detected.
Statistical analysis
The individual dog was the experimental unit and the
primary endpoint was the live flea count. Data for post-
treatment flea counts were summarized with arithmetic
(AM) and geometric (GM) means by treatment group
and time point. Flea counts were transformed (log
e(count + 1)) prior to analysis to stabilize the variance
and normalize the data. Using the PROC MIXED pro-
cedure (SAS 9.2, Cary NC), transformed counts were an-
alyzed using a mixed linear model. The fixed effects
were treatment, time point and the interaction between
time point and treatment by time point. The random
effects included block, block by treatment interaction,
and error. Testing was two-sided at the significance level
α = 0.05.
The assessment of efficacy was based on the percent
reduction in the arithmetic and geometric mean live flea
counts relative to placebo calculated using Abbott’s
formula:
% reduction ¼ 100  mean count placeboð Þ–mean count treatedð Þ
mean count placeboð Þ
Results
There were no treatment-related adverse events during
the study. Placebo-treated dogs maintained good flea in-
festations throughout the study and these counts were
maintained even following the combing and re-
infestation procedures at 8 and 12 h (Tables 1, 2 and 3).
At the 8-h time point, both treatments resulted in sig-
nificantly lower flea counts than placebo-treated dogs
(P ≤ 0.0021) throughout the study (Table 1). Treatment
with sarolaner resulted in significantly lower flea counts
than spinosad/milbemycin oxime at 8 h on Days 21, 28,
and 35 (P < 0.0085). The sarolaner treatment provided
greater and more consistent efficacy at 8 h, with efficacy
>96.9 % (GM and AM) from treatment through Day 28.
Efficacy for spinosad/milbemycin oxime was <95 % on
Days 21 to 35 (AM) and on Days 28 and 35 (GM)
(Table 1).
At the 12-h time point, both treatments resulted in
significantly lower flea counts than placebo-treated
dogs (P ≤ 0.0001) throughout the study (Table 2). Flea
counts were significantly lower for sarolaner-treated
dogs than spinosad/milbemycin oxime-treated dogs on
Day 35 (P < 0.0001). Efficacy was very high for sarola-
ner with all dogs being flea-free on all study days, while
live fleas were detected on spinosad/milbemycin oxime
treated dogs from Day 21 through Day 35. Efficacy of
spinosad/milbemycin oxime declined as the study pro-
gressed (Fig. 1); at Days 21 to 35 efficacy for spinosad/
milbemycin oxime-treated dogs was <95 % (AM), and
on Day 35 (GM) (Table 2).
At the 24-h time point, both treatments resulted in
significantly lower flea counts than placebo-treated
dogs (P ≤ 0.0001) throughout the study (Table 3). Flea
counts were significantly lower for sarolaner-treated
dogs than spinosad/milbemycin oxime-treated dogs on
Day 35 (P = 0.0002). Sarolaner remained 100 % effect-
ive at 24 h post treatment, with all dogs flea free from
treatment through Day 35, while live fleas were detected
on spinosad/milbemycin oxime-treated dogs from Day 21
onwards. Efficacy for spinosad/milbemycin oxime
declined below 95 % by Day 28 based on AM and on Day
35 based on GM (Table 3, Fig. 1).
Discussion
A single oral dose of sarolaner provided rapid reduc-
tion of an existing infestation of fleas as well as subse-
quent weekly re-infestations for 35 days; efficacy was
≥99.1 % based on GM (≥96.9 %, based on AM) from
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Table 1 Mean live flea counts and efficacy relative to placebo at 8 h after treatment and post-treatment re-infestations for dogs
treated with a single oral dose of sarolaner or spinosad/milbemycin oxime on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 80–100 45–100 71–100 70–100 85–100 74–100
A. mean 91.8 86.0 87.4 87.8 96.1 86.6
G. mean1 91.5a 83.9a 86.7a 87.3a 96.0a 86.3a
Sarolaner Range 0–0 0–1 0–0 0–2 0–18 0–56
A. mean 0.0 0.1 0.0 0.3 3.0 14.9
Efficacy (%) 100 99.9 100 99.7 96.9 82.8
G. mean1 0.0b 0.1b 0.0b 0.1c 0.8c 5.2c
Efficacy (%) 100 99.9 100 99.8 99.1 94.0
P-value vs.placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Spinosad/milbemycin oxime Range 0–0 0–0 0–0 0–50 0–69 0–73
A. mean 0.0 0.0 0.0 9.1 22.3 38.4
Efficacy (%) 100 100 100 89.6 76.9 55.7
G. mean1 0.0b 0.0b 0.0b 2.6b 5.3b 23.1b
Efficacy (%) 100 100 100 97.0 94.4 73.2
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0021
P-value vs. sarolaner 1.000 0.8420 1.000 0.0085 0.0049 0.0020
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Table 2 Mean live flea counts and efficacy relative to placebo at 12 h after treatment and post-treatment re-infestations for dogs
treated with a single oral dose of sarolaner or spinosad/milbemycin oxime on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 84–100 19–96 80–100 67–100 80–97 66–98
A. mean 92.0 77.0 87.3 86.6 87.3 81.8
G. mean1 91.8a 70.7a 87.1a 85.9a 87.1a 81.2a
Sarolaner Range 0–0 0–0 0–0 0–0 0–0 0–0
A. mean 0.0 0.0 0.0 0.0 0.0 0.0
Efficacy (%) 100 100 100 100 100 100
G. mean1 0.0b 0.0b 0.0b 0.0b 0.0b 0.0c
Efficacy (%) 100 100 100 100 100 100
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Spinosad/milbemycin oxime Range 0–0 0–0 0–0 0–36 0–64 0–68
A. mean 0.0 0.0 0.0 4.5 9.5 27.9
Efficacy (%) 100 100 100 94.8 89.1 65.9
G. mean1 0.0b 0.0b 0.0b 0.6b 1.3b 8.2b
Efficacy (%) 100 100 100 99.3 98.5 90.0
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-value vs. sarolaner 1.000 1.000 1.000 0.2996 0.0538 <0.0001
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
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Table 3 Mean live flea counts and efficacy relative to placebo at 24 h after treatment and post-treatment re-infestations for dogs
treated with a single oral dose of sarolaner or spinosad/milbemycin oxime on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 69–100 11–96 73–89 60–100 69–94 15–100
A. mean 83.1 75.5 80.5 85.8 84.0 78.5
G. mean1 82.7a 65.8a 80.3a 84.7a 83.7a 70.1a
Sarolaner Range 0–0 0–0 0–0 0–0 0–0 0–0
A. mean 0.0 0.0 0.0 0.0 0.0 0.0
Efficacy (%) 100 100 100 100 100 100
G. mean1 0.0b 0.0b 0.0b 0.0b 0.0b 0.0b
Efficacy (%) 100 100 100 100 100 100
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Spinosad/milbemycin oxime Range 0–0 0–0 0–0 0–6 0–54 0–68
A. mean 0.0 0.0 0.0 0.8 6.8 19.6
Efficacy (%) 100 100 100 99.1 92.0 75.0
G. mean1 0.0b 0.0b 0.0b 0.3b 0.7b 4.3c
Efficacy (%) 100 100 100 99.7 99.2 93.9
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-value vs. sarolaner 1.000 1.000 1.000 0.5758 0.2499 0.0002
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Fig. 1 Percent efficacy based on geometric mean counts relative to placebo at 8,12 and 24 h after treatment and weekly post-treatment re-infestations of
fleas for dogs treated with a single oral dose of sarolaner or spinosad/milbemycin oxime on Day 0
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treatment through Day 28 and 94.0 % (GM) or 82.8 %
(AM) on Day 35 at 8 h after treatment or re-
infestation. By 12 and 24 h after treatment or re-
infestation, efficacy of sarolaner was 100 % (all dogs
were free of fleas) for the entire 35 day period. A simi-
lar speed of kill was attained for only 14 days at 8 h
after treatment or re-infestation with a single oral dose
of spinosad/milbemycin oxime, and from Day 21 on-
wards its speed of kill was significantly slower than
that of sarolaner. Even at 12 and 24 h after re-
infestation, significantly more live fleas were found on
spinosad/milbemycin oxime-treated dogs on Day 35
and efficacy at 12 h declined below 95 % from Day 21
onwards (AM) and on Day 35 (GM), and at 24 h effi-
cacy was <95 % from Day 28 onwards (AM) and on
Day 35 (GM). In contrast sarolaner-treated dogs were
free of fleas (100 % AM and GM) at 12 and 24 h for the
entire 35 days.
A rapid onset of activity and consistent speed of kill
for any parasiticide providing flea control is essential
to ensure that any newly acquired fleas are rapidly
eliminated before they can reproduce to help elimin-
ate the environmental infestation, decrease the likeli-
hood of transmission of vector-borne disease and
assist in the management of flea allergic dermatitis.
This provides the pet with rapid relief from the irrita-
tion and debilitating effects of the existing infestation
and protects it from new infestations. A single oral
treatment of sarolaner at the proposed commercial
dose of 2 to 4 mg/kg resulted in the rapid reduction
of an existing flea infestation as well as rapid kill of
newly infested fleas for at least 35 days, and efficacy
was more consistent over the full month with signifi-
cantly faster kill of fleas than spinosad/milbemycin
oxime from Day 21 onwards.
Conclusions
Both products resulted in rapid control of an exist-
ing flea infestation. Fleas were eliminated from all
dogs within 8 h and dogs remained flea-free at 24 h.
Against re-infestations, efficacy of sarolaner at 8 h
was significantly superior to spinosad/milbemycin
oxime on Days 21 to 35 and at 12 and 24 h on Day
35. The efficacy of spinosad/ milbemycin oxime
waned at the end of the month long treatment inter-
val, while sarolaner maintained high efficacy with all
dogs being flea free by 12 h from treatment through
Day 35. The rapid and consistent speed of kill of
fleas over a period of 35 days makes sarolaner chew-
able tablets (Simparica™) an excellent option for
monthly flea control that will reduce the direct irri-
tation caused by flea infestation, assist in the preven-
tion of FAD, and reduce the risk of flea-borne
diseases.
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